Teniposide

Generic name
Teniposide
Brand name
ATC Code
L01CB02
Compare …

Teniposide

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No information

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Oncological conditions
  • Intravenous
    • 1 month up to 18 years

      • The dose and dosing frequency of cytostatic agents depend on the condition and are very much subject to new insights. Cytostatic drugs are mostly used in oncology and haematology in combinations. For this reason, please refer to the detailed treatment protocols.

        The following indicative dosages have been stated by the manufacturer: The total dose per cycle is 300 mg/m², administered over a period of 3-5 days.

Renal impaiment in children > 3 months

GFR ≥10 ml/min/1.73m2: Dose adjustment not required.

GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

Extravasation: Severe reactions are not to be expected.

General cytostatic: a range of cytostatics can trigger hypersensitivity reactions. An emergency set (containing epinephrine, clemastine and hydrocortisone) should be present in the treatment room. The emergency set also contains specific antidotes.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Vinca alkaloids and analogues
L01CA01
L01CA02
Podophyllotoxin derivatives
L01CB01
Taxanes
L01CD02
Topoisomerase 1 (TOP1) inhibitors
L01CE02

References

  1. Rademaker C.M.A. et al, Geneesmiddelen-Formularium voor Kinderen, 2007
  2. Bristol Myers Squibb BV, SPC Vumon (RVG 05839), www.cbg-meb.nl, Geraadpleegd 09 juli 2010, http://db.cbg-meb.nl/IB-teksten/h08539.pdf

Changes

Therapeutic Drug Monitoring


Overdose